{
    "Trade/Device Name(s)": [
        "Vantera Clinical Analyzer",
        "NMR LipoProfile\u00ae test on Vantera Clinical Analyzer"
    ],
    "Submitter Information": "LipoScience, Inc.",
    "510(k) Number": "K133849",
    "Predicate Device Reference 510(k) Number(s)": [
        "K113830"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NSU",
        "MRR",
        "LBS",
        "CDT"
    ],
    "Summary Letter Date": "September 19, 2014",
    "Summary Letter Received Date": "September 22, 2014",
    "Submission Date": "September 18, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.2570",
        "21 CFR 862.1475",
        "21 CFR 862.1705"
    ],
    "Regulation Name(s)": [
        "Instrumentation for clinical multiplex test system",
        "Lipoprotein test system",
        "Triglyceride test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "LDL particle number (LDL-P)",
        "HDL cholesterol (HDL-C)",
        "Triglycerides"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Vantera Clinical Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Nuclear magnetic resonance (NMR) spectroscopy"
    ],
    "Methodologies": [
        "Spectroscopic detection",
        "Spectral deconvolution analysis",
        "Automated laboratory test analysis"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Vantera Clinical Analyzer and NMR LipoProfile test, using NMR spectroscopy to quantify lipoprotein particles in serum and plasma for cardiovascular risk assessment",
    "Indications for Use Summary": "Used to measure lipoprotein particles to quantify LDL-P, HDL-C, and triglycerides in human serum and plasma to aid in the management of lipoprotein disorders associated with cardiovascular disease",
    "fda_folder": "Clinical Chemistry"
}